A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease.
about
The Evolutionary Dynamics of a Rapidly Mutating Virus within and between Hosts: The Case of Hepatitis C VirusUltrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome PredictorsAnalysis of precore/core covariances associated with viral kinetics and genotypes in hepatitis B e antigen-positive chronic hepatitis B patients.Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomesThe roles of immune memory and aging in protective immunity and endogenous reactivation of tuberculosis.Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapyA perspective on modelling hepatitis C virus infection.Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)Sloppy models, parameter uncertainty, and the role of experimental designMathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?Estimating biologically relevant parameters under uncertainty for experimental within-host murine West Nile virus infection.A multifaceted approach to modeling the immune response in tuberculosis.Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now.On the laws of virus spread through cell populations.The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.The impact of hepatitis A virus infection on hepatitis C virus infection: a competitive exclusion hypothesis.Hepatitis C treatment response kinetics and impact of baseline predictors.Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?The Role of Infected Cell Proliferation in the Clearance of Acute HBV Infection in Humans.Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics.Dynamics of a Viral Infection Model with General Contact Rate between Susceptible Cells and Virus Particles
P2860
Q27490256-7B8F1758-0E23-451C-B3F8-A916EFF473CAQ28553721-8965DB05-1B62-43E0-AB90-1500F6BBB03CQ34182782-8E450E21-B4F4-4024-886A-1D1E54463E96Q34208650-0F8E5328-792A-4CCC-9C00-FA64A898F740Q34666081-CC32D754-F208-4EF9-831D-1E2289B9D25EQ34675037-08A0C844-C4B3-4D1F-931C-56AADA748BBBQ34759489-FFC0A267-A202-4A3B-830A-33C82256B05DQ34788785-7F2A6701-6108-4B61-95A6-5A51352778A3Q35610571-A6FD243A-EE79-40D6-BE81-2F8F202294DCQ35878898-17C7AC82-0748-499C-B804-1F14B6963EADQ36419726-6325F924-E0CE-4C57-9D2C-012C6E195D3FQ36810400-D16BB421-2844-492F-8F14-6D7974C5A9BFQ36921042-2508AC04-6185-4B8E-A41C-294BC5DBFD51Q37825461-56183097-BE0A-4ABA-B6AB-12D8F1196C78Q38548066-409A6CDF-0A82-431B-816C-052FAAA87D3EQ41754641-BE577304-4A12-47BE-9E6F-25585BCCAB0AQ42981009-0F0A9037-735E-41BE-AEF6-64606C7D6AE7Q42986690-B2947121-F216-482D-80A1-944ABE3A01D1Q42997280-8D02673B-8326-475E-87E1-34920BC196B4Q43042510-99DCA2E8-5618-49E3-9EBE-F1628775F97DQ47131005-3B5E8449-DE68-4E6B-8A10-2DC85ED3B756Q54254238-D155E2E2-0723-4439-9E45-01FEC3D7EDA5Q59039363-B3A082AF-17EA-46EB-BD5F-A610D49A6226
P2860
A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A mathematical model of hepati ...... ads or advanced liver disease.
@ast
A mathematical model of hepati ...... ads or advanced liver disease.
@en
type
label
A mathematical model of hepati ...... ads or advanced liver disease.
@ast
A mathematical model of hepati ...... ads or advanced liver disease.
@en
prefLabel
A mathematical model of hepati ...... ads or advanced liver disease.
@ast
A mathematical model of hepati ...... ads or advanced liver disease.
@en
P2093
P2860
P1433
P1476
A mathematical model of hepati ...... ads or advanced liver disease.
@en
P2093
Eric Kallwitz
Harel Dahari
Jennifer E Layden-Almer
Scott J Cotler
Thomas J Layden
P2860
P304
P356
10.1053/J.GASTRO.2008.12.060
P407
P577
2009-01-01T00:00:00Z